Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Augsburg – page 14

300 clinical trials in Augsburg, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Augsburg at a glance
300
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

300 trials in Augsburg

Open in trial search

Acute lymphocytic leukaemia

Not yet recruiting

Study of blinatumomab plus drug combination in children and adolescents with acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Not yet recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Borderline personality disorder

Not yet recruiting

A study to evaluate the effectiveness and safety of AP707 in patients with borderline personality disorder.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

Not yet recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Trospium Chloride
  • Sponsor:European Group for Research in Schizophrenia Stichting

Colorectal cancer metastatic

Not yet recruiting

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Augsburg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on breast cancer, lung cancer, and lymphoma treatments. Studies evaluating novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • HR-positive breast cancer treatment evaluation
  • Advanced non-small cell lung cancer therapies
  • Lymphoma and leukemia interventions

Several trials are investigating combination therapies to improve patient outcomes in various cancer types.

02 Dermatology Studies

Comprehensive research into plaque psoriasis and atopic dermatitis, with multiple trials testing new therapeutic agents and preventive approaches.

  • Moderate to severe psoriasis treatments
  • Preventive interventions for atopic dermatitis
  • Long-term safety assessments

Focus on both treatment and prevention strategies for chronic skin conditions.

03 Gastrointestinal Research

Innovative studies addressing ulcerative colitis and gastroparesis, testing novel therapeutic approaches and treatment combinations.

  • Ulcerative colitis treatment optimization
  • Gastroparesis symptom management
  • Biliary tract cancer therapies

Trials aim to improve quality of life and treatment outcomes for patients with chronic digestive conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.